Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.72 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.72 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.72 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.68 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.68 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566229 | 1.00 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL42134 | 1.00 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14199627 | 1.00 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14178408 | 1.00 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL912472 | 0.90 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL24211446 | 0.90 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2635506 | 0.90 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL18660222 | 0.89 | P2RY6 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL17577501 | 0.89 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL12701345 | 0.89 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | claimed |
| EP-2909223-B1 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2016014527-A2 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8853376-B2 | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics | ARCHEMIX LLC (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140112886-A1 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2014-04-24 | — | — | US | disclosed |
| US-20140065223-A1 | PERFLUORINATED COMPOUNDS FOR THE NON-VIRAL TRANSFER OF NUCLEIC ACIDS | Libera-Koerner, Jeanette (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20120171304-A1 | Stabilized Aptamers To Platelet Derived Growth Factor And Their Use As Oncology Therapeutics | ARCHEMIX LLC | 2012-07-05 | — | — | US | disclosed |
| US-8187597-B2 | Combination therapy for the treatment of ocular neovascular disorders | OPHTHOTECH CORPORATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100119522-A1 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | OPHTHOTECH CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | NUDT1, DUT, ADAR | SLC28A1 130/4885SLC28A2 131/4885SLC29A1 51/4885 |
| US-20140112886-A1 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION | NSUN2, NUDT1, NSUN3 | SLC28A1 12/4885SLC28A2 14/4885SLC29A1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.